Clinical Study

Dialysis Efficiency of AN69, a Semisynthetic Membrane Not Well Suited for Diffusion

M. E. Herrera-Gutiérrez, G. Seller-Pérez, D. Arias Verdu, C. Jironda-Gallegos, M. Martín-Velázquez, and G. Quesada-García

1 ICU, Carlos Haya Hospital, Carlos Haya Avenue s/n, 29010 Málaga, Spain
2 Nephrology, Carlos Haya Hospital, 29010 Málaga, Spain

Correspondence should be addressed to M. E. Herrera-Gutiérrez; mehguci@gmail.com

Received 3 October 2012; Accepted 14 November 2012

Academic Editors: D. G. Struijk and A. Tzamaloukas

Copyright © 2013 M. E. Herrera-Gutiérrez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

AN69 membrane is not suited for diffusion, with an suggested limit at 25 mL/min dialysate flow rate. When prescribing continuous hemodialysis this threshold must be surpassed to achieve. We designed a study aimed to check if a higher dose of dialysis could be delivered efficiently with this membrane. Ten ICU patients under continuous hemodiafiltration with 1.4 m² AN69 membrane were included and once a day we set the monitor to exclusively 50 mL/min dialysate flow rate and 250 mL/min blood flow rate and after 15 minutes measured dialysate saturation for urea, creatinine, and β2-microglobulin. We detected that urea saturation of dialysate was nearly complete (1.1 ± 0.09) for at least 40 hours, while creatinine saturation showed a large dispersion (0.86 ± 0.22) and did not detect any relation for these variables with time, blood flow, or anticoagulation regime. Saturation of β2-microglobulin was low (0.34 ± 0.1) and decreased discretely with time ($r^2 = 0.15$, $P < 0.05$) and significantly with TMP increases ($r^2 = 0.31$, $P < 0.01$). In our experience AN69 membrane shows a better diffusive capability than previously acknowledged, covering efficiently the range of standard dosage for continuous therapies. Creatinine is not a good marker of the membrane diffusive capability.

1. Introduction

Continuous renal replacement therapies (CRRT) have changed substantially the last two decades. Developed as a practical method to treated acute kidney failure in unstable patients and based in the use of convection, in the first stages a low solute clearance capability was characteristic and subsequent changes (as an early shift from an arterial-vena to a vena-vena approach) [1] were aimed to improve performance. To raise the clearance of uremic toxins, CRRT procedures evolved to slightly different methods like continuous hemodiafiltration (CHDF) [2] or continuous hemodialysis (CHD) [3] because a supplementary diffusive transport can improve the clearance of low molecular weight toxins, such as urea [4].

Dosage delivered as convective treatment can theoretically be raised without limits but in the real practice we have a limiting factor, that is, blood flow. When this limit has been reached to augment the dialysate flow seems an attractive alternative but some early reports demonstrated that when we set the dialysate over 25 mL/min, efficiency of the treatment is seriously compromised and this effect is related to the membrane involved [5].

In our unit, the weaning from CRRT is usually performed with slow intermittent dialysis delivered with the same CRRT monitor, in sessions lasting 10–12 hours. During this weaning phase some patients require a dose of dialysis theoretically surpassing the capability of the AN609 membrane. We designed this study to detect whether high dose dialysis performed with a membrane of low diffusive capability (AN69) was able to fulfill efficiently the requirements for our patients.

Our objective was to determine if a higher dose of dialysis could be delivered efficiently with this membrane.

2. Methods

We conducted a prospective observational study, collecting data from 10 ICU patients with acute kidney injury managed with CHDF.
2.1. CRRT Protocol. CHDF is conducted in our unit with a Prismaflex monitor (Hospal) and a 1.4 m² AN69 membrane filter (HF-1400, Hospal). Bicarbonate buffered fluid is infused in postdilution mode and the anticoagulant regime is adjusted to the clinical condition of the patient [6], using three alternatives: nonfractionated heparin at 5 U/Kg/h, epoprostenol at 5 ng/Kg/min, or no anticoagulation. Initial prescribed dose is 35 mL/Kg/h, with the convective component as high as possible (according to catheter performance and keeping filtration fraction below 20%); when the complete dose cannot be achieved the rest is delivered as dialysis. When the patient is hemodynamic stable the dose is lowered, aiming for internal milieu normality, and usually convective and diffusive components are equaled. Finally, the weaning process is performed with slow intermittent dialysis delivered with the Prismaflex monitor in sessions lasting 10–12 hours every day. During the weaning phase of the treatments some patients require a dose of dialysis theoretically surpassing the capability of the AN609 membrane. So we designed this protocol to assure that an efficient treatment was delivered.

2.2. Measurements. Every day and during the morning shift, treatment prescription was changed temporarily to a blood flow \( Q_b \) of 250 mL/min, a dialysate flow rate \( Q_d \) of 50 mL/min (3 L/h), and zero ultrafiltration/zero negative balance; anticoagulation was maintained without changes. The monitor was kept running for 15 minutes before samples were taken and then was immediately reverted to the original prescription for each patient. Transmembrane pressure (TMP) and anticoagulation regime at this time were registered for each measure.

Blood samples were taken pre- and postfilter using the ports in the circuit and a sample of the effluent was extracted from the port in the effluent line. Samples were transferred immediately to the laboratory for determination of urea, creatinine, and \( \beta_2 \)-microglobulin.

Saturation of the dialysate was calculated using the equation:

\[
\text{Saturation} = \frac{[E_f]}{([I_n] + [O_a])/2},
\]

where \([E_f]\) is the concentration of a solute in the effluent, \([I_n]\) is the concentration in the before filter blood sample, and \([O_a]\) is the concentration in the after filter sample.

2.3. Statistical Analysis. Data are shown as mean (standard deviation) or n (percentage). To test hypothesis we used U Mann-Whitney or Kruskal-Wallis, and for the study of the relationship between continuous variables a linear regression analysis was performed. A 0.05-signification level was used for all tests.

3. Results

We performed 44 measurements in 10 patients, with a median of 3 measures/patient (in 3 patients 1 measure and in one 16 measures).

All patients were treated with bicarbonate bufferedhemodiafiltration with a mean \( Q_b \) of 241 ± 37.1 mL/min and a mean dose \( (Q_d) \) of 2506 ± 69 mL/h. Mean TMP at the moment of the measurement was 81 ± 60 mmHg and the anticoagulant regime employed at this point was heparin in 18 (40.9%), epoprostenol in 9 (20.5%), and none in 17 (38.6%) measures.

Mean saturation of dialysate was 1.08 ± 0.09 for urea and 0.86 ± 0.22 for creatinine \((P < 0.001)\), and the relationship between both measures showed a wide distribution of data (Figure 1). Mean saturation of \( \beta_2 \)-microglobulin was 0.34 ± 0.12.

We detected a decrement of \( \beta_2 \)-microglobulin in relation to filters running time \((r^2 = 0.15, P < 0.05)\) and not for urea or creatinine but, while urea saturation was close to 1 without evident changes in time, creatinine saturation showed an erratic behavior with a wide dispersion of data (Figure 2). A fall in dialysate saturation following an increment of TMP was observed for the three molecules, more marked for \( \beta_2 \)-microglobulin than urea or creatinine and once more with a wide dispersion for the last one (Figure 3). The anticoagulant regime employed did not interfere with the results (Table 1).

4. Discussion

Dose prescription in CRRT has risen steadily since the appearance of these therapies. The best dose is an open debate [7–10] but in practice is markedly higher than two decades ago. Other aspect under debate is whether this dose must be delivered as convection, diffusion, or both but the most widely employed modality is mixed CHDF [11–13]. When prescribing CRRT, synthetic membranes with low diffusive performance are employed and a raise in the dialysate flow rate will not be always followed by a proportional increment in dose. As a general rule, keeping dialysate flow rate below 25–30 mL/min has been considered adequate [14, 15] but our results demonstrate that with a 1.4 m² AN69 membrane this threshold can be raised up to 50 mL/min (3 L/h) while keeping dialysate saturation in the optimal range.
When prescribing CRRT, high permeability synthetic membranes are used and some of these membranes show a low performance in diffusion [16]. The classical membrane requirement to be met with respect to diffusive clearance has been in the past the complete saturation of the dialysate at flow rates up to 30 mL/min [5] because beyond this boundary the ability to completely saturate the dialysate begins to fall [16]. This effect is potentially more significant when using polyamide compounds, which show low diffusive transport properties [17]. Now we can confirm that a complete saturation of the dialysate should be expected with flows up to 50 mL/min (3 L/h) (nearing the dose achieved with other diffusive treatments like SLEDD) [18–20].
The results are only valid when CHD is performed with a 1.4 m% th e lose of external validity of our results. Consequently, our conclusions do not apply when a mixed modality (hemodiafiltration) when some interaction should be expected. In these cases, when a high dialysate flow is prescribed, we think it is advisable to measure effluent saturation to ensure an adequate dialysis delivery.

We have detected a significant difference in the urea and creatinine saturation; while the first one behaved as a good marker for saturation (all the data obtained from urea were consistent and narrowly distributed close to unity), creatinine showed a wide dispersion of data and is our conclusion that creatinine is not an adequate marker for dialysate saturation. We have no explanation for this finding but in part could be reflecting a problem with the determination of creatinine; our laboratory uses the Jaffe technique, known to show variations ranging from 5.3 to 27.4 μmol/L [22].

We must acknowledge some biases in our results. The first one lays in the fact that we did perform the measures in a “laboratory” setting by standardizing the modality and not analyzing the patients who were really being treated. Consequently, our conclusions do not apply when a mixed (convective-diffusive) therapy is performed. Our main objective was to detect the capability of the membrane to deliver a high dose of dialysis so opted for the use of this modality alone, limiting possible confounding factors and assuming the lose of external validity of our results.

An other limiting factor is the material employed; our results are only valid when CHD is performed with a 1.4 m² AN69 membrane but, being this synthetic membrane the less efficient for diffusion, we believe that 50 mL/min can be considered a reasonable minimum for any other synthetic membrane employed in CRRT.

Even though the number of measures was adequate to perform the analysis, the number of patients recruited is small and did not let us introduce patient related factors that hypothetically could have altered our results; so our conclusions must be understood as technically and not clinically oriented until more studies are published, but the similitude between our findings and those of Ricci et al. [17] is encouraging and support our conclusions.

We conclude that the AN69 membrane shows a higher diffusive performance than previously reported, up to 50 mL/min, covering efficiently the range of standard dosage for continuous therapies.

Conflict of Interests

All the authors state that they do not have a direct financial relation with the commercial identities mentioned in this paper that might lead to a conflict of interests. The brand names stated in the paper were presented because this is a technical paper and the reader must be completely aware of the materials employed in this research.

Acknowledgment

This is an original work and has not been published nor sent for consideration to other journals but preliminary results were presented in the Spanish Congress of the Spanish Nephrology Society and the European Congress of the ESICM in 2009. All the authors have had an active role in the research and all acknowledge and approve the content of the paper.

References

[1] W. L. Macias, B. A. Mueller, S. K. Scarim, M. Robinson, and D. W. Rudy, "Continuous venovenous hemofiltration: an alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure," American Journal of Kidney Diseases, vol. 18, no. 4, pp. 451–458, 1991.
[2] R. Geronemus and N. Schneider, "Continuous arteriovenous hemodialysis: a new modality for treatment of acute renal failure," Transactions of the American Society For Artificial Internal Organs, vol. 30, pp. 610–613, 1984.
[3] P. Y. W. Tam, S. Huraib, B. Mahan et al., "Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit," Clinical Nephrology, vol. 30, no. 2, pp. 79–85, 1988.
[4] C. Bredahl, G. Nielsen, and U. T. Larsen, "Continuous arteriovenous hemodialysis in acute renal insufficiency. Review of therapeutical results among 23 patients treated over a period of 2 years," Ugeskriift for Laeger, vol. 153, no. 38, pp. 2628–2631, 1991.
[5] S. Relton, A. Greenberg, and P. M. Palevsky, "Dialysate and blood flow dependence of diffusive solute clearance during CVVHD," ASAIO Journal, vol. 38, no. 3, pp. M691–M696, 1992.
[6] M. E. Herrera-Gutiérrez, G. Seller-Pérez, M. Lebrón-Gallardo, J. P. De La Cruz-Cortés, and J. A. González-Correa, "Use of isolated epoprostenol or associated to heparin for the maintenance of the patency of the continuous renal replacement technical circuits," Medicina Intensiva, vol. 30, no. 7, pp. 314–321, 2006.
[7] C. Ronco, R. Bellomo, P. Homel et al., "Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial," The Lancet, vol. 356, no. 9223, pp. 26–30, 2000.
[8] C. Vinsonneau, C. Camus, A. Combes et al., “Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial,” *The Lancet*, vol. 368, no. 9533, pp. 379–385, 2006.

[9] P. M. Palevsky, J. H. Zhang, T. Z. O’Connor et al., “Intensity of renal support in critically ill patients with acute kidney injury,” *New England Journal of Medicine*, vol. 359, no. 1, pp. 7–20, 2008.

[10] R. Bellomo, A. Cass, L. Cole et al., “Intensity of continuous renal-replacement therapy in critically ill patients,” *New England Journal of Medicine*, vol. 361, no. 17, pp. 1627–1638, 2009.

[11] C. Ronco, M. Zanella, A. Brendolan et al., “Management of severe acute renal failure in critically ill patients: an international survey in 345 centres,” *Nephrology Dialysis Transplantation*, vol. 16, no. 2, pp. 230–237, 2001.

[12] M. E. Herrera-Gutiérrez, G. Seller-Pérez, J. Maynar-Moliner, and J. A. Sánchez-Izquierdo-Riera, “Epidemiology of acute kidney failure in Spanish ICU. Multicenter prospective study FRAMI,” *Medicina Intensiva*, vol. 30, no. 6, pp. 260–267, 2006.

[13] S. Uchino, J. A. Kellum, R. Bellomo et al., “Acute renal failure in critically ill patients: a multinational, multicenter study,” *Journal of the American Medical Association*, vol. 294, no. 7, pp. 813–818, 2005.

[14] S. Brunet, M. Leblanc, D. Geadah, D. Parent, S. Courteau, and J. Cardinal, “Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates,” *American Journal of Kidney Diseases*, vol. 34, no. 3, pp. 486–492, 1999.

[15] R. Bellomo and C. Ronco, “Continuous renal replacement therapy in the intensive care unit,” *Intensive Care Medicine*, vol. 25, no. 8, pp. 781–789, 1999.

[16] Z. Ricci and C. Ronco, “Dose and efficiency of renal replacement therapy: continuous renal replacement therapy versus intermittent hemodialysis versus slow extended daily dialysis,” *Critical Care Medicine*, vol. 36, no. 4, pp. S229–S237, 2008.

[17] Z. Ricci, C. Ronco, A. Bachetoni et al., “Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion,” *Critical Care*, vol. 10, no. 2, p. R67, 2006.

[18] B. Manns, C. J. Doig, H. Lee et al., “Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery,” *Critical Care Medicine*, vol. 31, no. 2, pp. 449–455, 2003.

[19] N. Srisawat, L. Lawsin, S. Uchino, R. Bellomo, and J. A. Kellum, “Cost of acute renal replacement therapy in the intensive care unit: results from the beginning and ending supportive therapy for the kidney (BEST Kidney) study,” *Critical Care*, vol. 14, no. 2, p. R46, 2010.

[20] V. A. Kumar, M. Craig, T. A. Depner, and J. Y. Yeun, “Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit,” *American Journal of Kidney Diseases*, vol. 36, no. 2, pp. 294–300, 2000.

[21] R. Venkataraman, J. A. Kellum, and P. Palevsky, “Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States,” *Journal of Critical Care*, vol. 17, no. 4, pp. 246–250, 2002.

[22] N. Pannu, S. Klarenbach, N. Wiebe, B. Manns, and M. Tonelli, “Renal replacement therapy in patients with acute renal failure: a systematic review,” *Journal of the American Medical Association*, vol. 299, no. 7, pp. 793–805, 2008.